Live Breaking News & Updates on Pharma Bavaria International
Stay updated with breaking news from Pharma bavaria international. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory approvals in South Korea, the fourth largest pharma market in Asia, and PanamaMaxigesic® IV provides a non-opioid, dual mode-of-action pain management alternative to traditional analgesics . ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth strategy Conference call and webcast today at 3pm CEST/9am EST (details below) Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month p ....
Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has extended its existing license and distribution agreement with Pharma Bavaria International for the commercialisation of Maxigesic IV, a novel, patented, non-opioid treatment for post-operative pain, in South America. The extended collaboration further builds on the agreement signed with Pharma Bavaria in February 2020 for the commercialisation of Maxigesic IV in 12 countries in Central America. Following multiple licensing deals with strong local players over the past 12 months, Maxigesic IV is now licensed in >100 countries across the globe, including the major markets in Europe and the U.S. The focus over the next 24 months will now shift towards accelerating regulatory submissions and launches in the ....